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Objectives: To determine the phenotype and frequency of Extended Spectrum Beta-Lactamase in Uro-pathogens 
in a tertiary care hospital of Nowshera. 
Material and methods: This Prospective cohort study was performed in the clinical pathology laboratory of Qazi 
Hussain Ahmed Medical Complex (QHAMC) Nowshera from 1st Jan 2019 to 30th May 2019. Relevant information 
was recorded on a predesigned proforma prepared as per CLSI Recommendation for data collection. 
Results: A total of 192 urine samples were received for Culture and sensitivity. Out of which 56 cases were ESBL 
phenotypically positive (29.16%). 39(69.9%) were females and 17(30.4%) were males. The age range of the patient 
was from 3 months to 63 years of age, with a mean age of 30 years with +5.4 SD Frequency of ESBL producing uro-
pathogens was;  51(91%) E-Coli, 4(7.1%) Klebsiella pneumonia and 1(1.8%) Proteus mirabilis. Out of 39 ESBL 
producing uro-pathogen in Female gender, E Coli-ESBL producing strains were isolated in 35 patients, Klebsiella 
Pneumonia in 3 patients and one case was of Proteus mirabilis-ESBL. In the male gender, 17 cases with E Coli-
ESBL were reported and one case of Kliebsilla Pneumonia ESBL. 
Conclusion: The prevalence of ESBL producers in the present study was quite alarming and challenging to the 
clinician in treating urinary tract infections. These types of resistant infections are a challenge to treat and a public 
health threat that needs accumulative response through advocacy, communication, and social mobilization. 
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Introduction 
 
ESBL is short for Extended-Spectrum Beta-Lactamase. 
ESBL is an enzyme found in some resistant strains of 
bacteria that are resistant to conventional antibiotics 
i.e. penicillins, cephalosporins, and monobactam. ESBL 
producing uro-pathogens causing urinary tract 
infection (UTI) has reported increased resistance to 
antimicrobial medications.1 Urinary tract infections 
(UTIs) are an important community and acquired 
infection reported worldwide.2  Escherichia coli (E. 
coli) is notorious for causing urinary tract infections 
(UTIs) and the uropathogenic E.Coli (UPEC) are 
reported to cause UTI in 90% of community-acquired 
and up to 50% cases of hospital-acquired UTIs.3,4 
UPEC is associated with an increased rate of 
expression of extended-spectrum β-lactamase (ESBL) 
gene. ESBLs contain plasmid-mediated derivatives. 
ESBLs, called CTX-M (i.e., “active on CefoTaXime, first 
isolated in Munich”) type, have been reported in 2000 
globally.5 
Since the treatment of UTI is started with the irrational 
use of antibiotics without the culture and sensitivity 
which is essential before attaining the desired 
objectives from the empirical therapy. This results in 
the production of ESBL by Micro-organism and the 
infection proceeds toward resistant type.6 The 
prevalence of ESBL-producing E.coli is rapidly 
increasing in our part of the world because of poor 
implementation of the rules and regulations about the 
rational use of antibiotics and increased in the 
quackery associated with the medical professional, 
minimal or negligible role of the drug regulatory 
authority and health care commission. 
The use of second and third-generation cephalosporins 
for the treatment of simple UTI has led to the 
development of resistant infection and the production 
of enzymes called the Extended Spectrum Beta 
Lactamases (ESBLs) that results in the development of 
multi-drug resistance.7 
There are many types of ESBLs like TEM, TEM given 
name, after the name of the patient who developed 
ESBL for the first time, named Temoniera from Greece, 
SHV type ESBL is another plasmid-mediated β-
lactamase is named after the sulphydryl variable and 
CTX for the ESBL that can hydrolyze the cefotaxime. 
OXA is another β-lactamase and it has hydrolytic 
activity against the cloxacillin and oxacillin. PER type 
of ESBL refers to resistance to penicillin’s and 
cephalosporins, VEB-ESBL is a β-lactamase first 
derived from a patient of Vietnam, GES-ESBL is b-
lactamase isolated from for Guiana patients.8 ESBL 
types of infections are strongly associated with high 
morbidity and mortality than other types of UTIs.9 
Extended-spectrum ß-lactamase (ESBL) producing 
bacteria causing infectious diseases conferring 
resistance to all ß-lactam antibiotics. ESBL-producing 
organisms frequently show cross-resistance to other 
antibiotics as well; including aminoglycosides and 
fluoroquinolones thus making treatment of these 
infections non-treatable.2,3 
The present study was designed to investigate the 
occurrence of plasmid-mediated ESBL resistance gene 
expression in various uro-pathogens using phenotypic. 
 
Materials and Methods 
 
This Prospective cohort study was performed in the 
Clinical Pathology Laboratory of Qazi Hussain Ahmed 
Medical Complex Nowshera from 1st Jan 2019 to 30th 
May 2019. A total of 192 urine samples were received 
for Culture and sensitivity out of which 56 cases 
reported being ESBL phenotypically positive (29.16%).  
The inclusion criteria were midstream urine of all 
cases irrespective of age and gender received in the 
laboratory. Exclusion criteria were urine samples 
received in the laboratory 24 hours after collection, the 
patient already on the antibiotic therapy and 
improperly collected urine. 
The specimen was received in the pathology section 
from the respective unit under observance of strict 
aseptic technique along with the education of patients 
on a midstream urine sample. Media were prepared as 
per CLSI (Clinical and laboratory standard institute).  
Then the urine samples were inoculated on CLED 
(Cysteine Lactose Electrolyte Deficient) media. Then 
the specimens were incubated under ambient air 35 +2 
C for 24 hours.  In case growth is obtained followed 
with inoculation on Mueller Hinton agar for sensitivity 
to antibiotics. For urine samples the antibiotic desks 
used were; Ak- Amikacin, Mem-Meropenem, IPM-
imepenum, CAZ-Ceftazadime, CTX-Cefotaxime, TZP- 
Piperacillin Tazobactum, SCF-Cefperazone Sulbactum, 
CT-Colistin Sulphate, F-Nitrofruantoin, AMC- 
Amoxicillin-Clavulanic acid, Fos-Fosfomycin, SXT-Co-
Triamaxazole, Levo-Levofloxacin & CIP-Ciprofloxacin. 
Plates were incubated for 18-20 hours and then the 
zone of inhibition was calculated on the caliper, 
including the size of the desk. Zones were compared 
with CLSI recommendations for sensitivity to be 
reported as sensitive, intermediate and resistant. 
Desk of AMC-amoxicillin- Clavulanic acid was placed 
at a distance of 25mm center to center to any of the 
following antibiotics; CRO-ceftriaxone-CTX-
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cefotaxime-CAZ-ceftazidime-ATM-Aztreonam. 
Phenotypically ESBL was confirmed as enhancement 
of zone of any of the indicator antibiotics (CRO-
ceftriaxone-CTX-cefotaxime-CAZ-ceftazidime-ATM-
Aztreonam) towards  AMC-amoxicillin Clavulanic 
acid was considered to be positive for ESBL 
phenomenon (Figure 1). 
Finally, the data obtained from the culture and 
sensitivity was entered into SPSS version 16 for 
descriptive and correlation analysis of different 
parameters. 
Descriptive statistics were used for numerical 
variables. The categorical variable frequency was 
shown in percentages likewise for gender and type of 
ESBL producing organisms. 
A chi-square test was applied to see the 
relationship/Preference of ESBL for the type of 
bacteria and a p-value of 0.05 was taken as significant. 
 




A total of 192 urine samples were received for Culture 
and sensitivity out of which 56 cases reported being 
ESBL phenotypically positive (29.16%). 39(69.9%) were 
females and 17(30.4%) males (Table 1).  
The age range of the patient was from 3months to 63 
years of age, with a mean age of 30 years with +5.4 SD. 
The mode of age was 25 years (Table 2).  
The frequency of ESBL producing uro-pathogens was; 
51(91%) cases in E-Coli, 4(7.1%) in Klebsiella 
pneumonia and 1(1.8%) in Proteus mirabilis (Table 3). 
29(51%) cases ESBL positive were reported from 
samples received from the Medical unit, 11(19.6%) 
from Surgery/Gyne unit and 8(14.3%) from Paeds 
Medicine and Accident and Emergency departments 
each (Table 4). 
Sensitivity pattern to ESBL was; Imepenum(IMP) 56 
(100%), Meropenum(Mem) 56 (100%), Amikacin(AK) 
56 (100%), (Piperacillin Tazobactum(TZP)  50(89.3%), 
Nitrofurantoin (F) 44(78.6%), Cefperazone Sulbactum 
(SCF) 43(76.8%), Fosfomycin (Fos) 42(75%),Co-
trimaxazole (SXZ) 15(26.8%) Levofloxacin, 
ciprofloxacin and colistin sulphate 5.4%  each(Table 5). 
In females, due to many reasons (mainly the short 
distance between the vagina and anus, because of 
increased colonization of bacteria in the vagina and 
increased sexual manipulation), the exposure to 
ESBLE was more common. Out of 39 ESBL cases in 
Female; E Coli-ESBL producing strains were found in 
35 patients, Klebsiella Pneumonia in 3 patients and in 
one case was  of Proteus mirabilis-ESBL. In the male 
gender, E Coli-ESBL was 16 and Klebsiella Pneumonia 
ESBL  in one case (Table 6). 
We received the ESBL cases in three gram-negative 
strains (E-coli, klebsiella, and proteus) 26,2,1 
respectively  from the Medical unit. The cases from 
Surgery and allied including the Gynecology 
department the ESBL in E-coli and Klebsiella (10,1 
respectively).  
From Paeds medicine and accident and emergency 
department 16 cases (8 from each unit) with ESBL 
producers frequency of 7, 1 for E-Coli and Klebsiella 
respectively (Table 7). 
 
Table 1. Descriptive Statistics 
 Gender Frequency 
n 
Percentage % 
Female 39 69.6 
Male 17 30.4 
Total 56 100.0 
 
Table 2.  Age Statistics 









Table 3. Table Frequency of ESBL Producing Uro-
Pathogens 
  Frequency Percentage % 
E.Coli 51 91.1 
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Klebsiella pneumonia 4 7.1 
Proteus mirabilis 1 1.8 
Total 56 100 
 
Table 4. Department wise ESBL Reporting 
Department Frequency Percent 
A/E Dept 8 14.3 
Medical 29 51.8 
Paeds Medicine 8 14.3 
Surgery/Gyne 11 19.6 
Total 56 100.0 
 
Table 5: Sensitivity pattern to ESBL 
Sensitivity to Antibiotic Frequency Percentage  
IPM-imepenum  56 100 







Ak-Amikacin 56 100 
F-nitrofurantoin 44 78.6 
Fos-Fosfomycin 42 75 
SXT- Co-Triamaxazole 15 26.8 
Levo-Levofloxacin 3 5.4 
CIP-Ciprofloxacin 3 5.4 
CT-Colistin sulphate 3 5.4 
 
Table 6. Gender and ESBL types Crosstabulation 
Gender E.Coli Klebsiella Proteus Total 
Female 35 3 1 39 
Male 16 1 0 17 
Total 51 4 1 56 
Pearson Chi-Square= 0.515, P-value= 0.773 
 
Table 7.  Department and ESBL types Cross-
tabulation 
Department E.Coli Klebsiella Proteu
s 
Total 
A/E Dept 8 0 0 8 
Medical 26 2 1 29 
Paeds 7 1 0 8 
Surgery 
/Gyne 
10 1 0 11 




Bacterial resistance to commonly used antibiotics in 
clinical practice has resulted in the evolution of a wide 
range of Extended-spectrum β-lactamase (ESBL) 
producing strains that is a global public health concern 
resulting in wastage of huge loss of economy on 
simple infections that have now become resistant due 
to ESBL production by the microbial.10 ESBL has failed 
in treatment strategies normally practiced up to 
secondary care treatment facilities where there are no 
facilities for culture and sensitivity. There is an 
increase in the reporting ratio of ESBL producing 
gram-negative bacteria from our set-ups especially by 
Enterobacteriaceae with diverse types of ESBL genes 
as mentioned above are alarming. ESBLs producing 
bacteria can hydrolyze the 3rd and 4th generation of 
cephalosporins, all types of penicillins and 
monobactams. These resistant strains are inhibited by 
β-lactamase inhibitors i.e.(clavulanic acid, sulbactam, 
and tazobactam).11,12 
In the present study, the ESBL production rate was 
29.16% lower as compared to other studies that have 
reported to be 52%. However  various other studies 
have reported the range of ESBL production rate from 
17% to 70%.13,14 
We detected the ESBL in uro-pathogens in the present 
study, many other studies have reported urine as the 
major source of ESBL producing microbial.15,16. One of 
the authors has, however, reported blood as a major 
source for isolating ESBL producing organisms.17 
In our study, the frequency of ESBL producing uro-
pathogens was 51(91%) in E-Coli, followed by 
Klebsiella pneumonia 4(7.1%) and Proteus mirabilis 
1(1.8%). Studies have reported  E. coli was the major 
ESBL producer that coincides with our findings.18,19 
Similarly, one study reported the highest ESBL 
production in Klebsiella spp.20 One author reported the 
prevalence of the CTX-M encoding gene in the 
majority of E. coli strains(96%) followed by K. 
pneumonia(71%)21 that phenotypically, however, 
matches our findings. 
In the present study, we found that in females due to 
the short distance between the vagina and anus, 
increased colonization of bacteria in the vagina lead to 
exposure to ESBL in the female gender. Out of 39 ESBL 
cases in the female gender, E Coli-ESBL producing 
strains were found in 35 patients, Klebsiella 
Pneumonia in 3 patients and one case was of Proteus 
mirabilis-ESBL. A study from Saudi Arabia reported 
that The ESBL phenotype was detected in 351 of 1151 
isolates (30.5%). Their phenotypic detection rate 
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coincides with our findings. Escherichia coli (E. coli) 
being the most common pathogen producing the ESBL 
(62.7%) followed by Klebsiella pneumonia(K. 
pneumoniae) (23.6%) that again matched our findings. 
 They reported that  The highest proportion of ESBL 
producing microbials were isolated from the urine 
samples(62.5%), and further that their majority of the 
target samples were reported from the female medical 
ward (20.2%)22 as seen in our findings.  
In present study the sensitivity pattern to ESBL was; 
Imepenum(IMP) 56 (100%), Meropenem(Mem) 56 
(100%), Amikacin(AK) 56 (100%), (Piperacillin 
Tazobactum(TZP)  50(89.3%), Nitrofurantoin (F) 
44(78.6%), Cefperazone Sulbactum (SCF) 43(76.8%), 
Fosfomycin (Fos) 42(75%),Co-trimoxazole (SXZ) 
15(26.8%) Levofloxacin, ciprofloxacin and colistin 
sulphate 5.4%  each. Many other studies have reported 
that the sensitivity pattern to  E. coli ESBL isolates was 
Imipenem (99.54%), Ampicillin-Sulbactam (97.48%), 
Piperacillin-Tazobactam (96.86%), Fosfomycin 
(94.51%), Amikacin (92.26%) and Nitrofurantoin 
(90.68%).23 While antibiotic sensitivity to K. 
pneumoniae ESBL isolates was imipenem (97.62%), 
Piperacillin-Tazobactam (95.35%), Ampicillin-
Sulbactam (90.48%) and Amikacin (88.37 %).23 Another 
study reported that the sensitivity pattern to E.Coli-
ESBL was amikacin (50.7%), SCF (51.4%), TZP (52.7%), 




The prevalence and incidence of ESBL-producing 
Enterobacteriaceae are high in Pakistan. Very little is 
reported from the Khyber Pukhtunkhwa province to 
know about the prevalence of ESBL in uro-pathogens. 
There is need for regular surveillance to address this 
antimicrobial resistance issue and to take remedial 
actions at different forums including the legislative 
reforms to ban quackery by strengthening Health Care 
Commission (HCC) Role and to develop proper 
protocols for prescribing antibiotics in Medical 
Teaching Institutions(MTI) and tertiary care treatment 
facilities and need for the clinicians and surgeon to 
reduce their ego and to value the recommendations of 
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